AN ACT Relating to the diabetes prevention and obesity treatment act;
SB 5353, titled the Diabetes Prevention and Obesity Treatment Act, requires health plans issued or renewed on or after January 1 to cover diagnosis and treatment of obesity as a chronic disease. Covered services include intensive health behavior and lifestyle treatment, metabolic and bariatric surgery, and FDA-approved obesity medications. The bill defines these treatment categories and specifies that intensive behavioral treatment may be delivered in person or through telemedicine.
The bill applies both to private health plans and, in a separate section, to the state authority and managed care organizations serving Medicaid-related coverage, contingent on federal authorization and matching federal funds. For the public program section, the authority must apply for federal approval by November 1 to receive federal matching funds for the covered services. The bill also states that utilization management may still be used to determine medical necessity, so long as those determinations are made in the same manner as for other covered conditions.
The bill’s impact on state law is to add new coverage mandates and definitions to Washington insurance and health care statutes, expanding required obesity treatment benefits and limiting how insurers may set coverage criteria. It also directs the state to seek federal approval for similar coverage under public health coverage programs, potentially affecting Medicaid managed care and other state-administered coverage arrangements. The bill further prohibits obesity treatment coverage from being treated differently than other illnesses for purposes of deductibles, copayments, coinsurance, and benefit-year maximums.
The general sentiment reflected in the bill text is strongly supportive of expanded access to obesity treatment, with a clear public-health framing that obesity is a chronic disease requiring evidence-based care. Because there are no committee transcripts or recorded votes provided, there is no documented floor or committee debate to indicate broader political support or opposition. The structure of the bill suggests an intent to normalize obesity treatment within standard insurance coverage rather than treat it as an optional or limited benefit.
The main point of potential contention is cost and utilization control. The bill requires broad coverage for behavioral treatment, surgery, and medication, which could increase premiums or program spending, while insurers and managed care organizations are explicitly allowed to continue applying utilization management and medical-necessity review. Another possible issue is the federal approval requirement for public coverage, since implementation for the state authority depends on CMS authorization and federal matching funds.
The bill would amend Washington insurance and health coverage law to require coverage for obesity diagnosis and treatment, including intensive behavioral therapy, bariatric surgery, and FDA-approved anti-obesity medications, and would add related definitions and parity rules for cost-sharing and benefit design. It also creates a parallel public-program framework directing the state to seek federal approval and matching funds to extend similar coverage through the authority and managed care organizations, while preserving utilization management standards.
The bill is framed in a supportive, health-expansion posture, emphasizing obesity as a chronic disease and seeking to broaden access to evidence-based treatment. No committee discussion or vote record is provided, so there is no direct evidence of opposition or amendment debate in the supplied materials. Based on the text alone, the measure appears designed to expand benefits rather than restrict them.
The likely areas of contention are the fiscal and administrative effects of mandating coverage for expensive treatments such as bariatric surgery and obesity medications, and whether insurers or managed care plans can continue to use utilization management to limit use. Another possible issue is the dependency on federal authorization for the public-program portion, which could delay or limit implementation. Supporters would likely emphasize access and preventive health, while opponents may focus on cost, medical necessity review, and program budget impacts.